In this progressing and increasingly competitive commercial landscape, attaining optimal market access is becoming extra challenging for pharmaceutical/medical device patrons. In the stir of the global economic crisis, ever increasing costs and abating healthcare budgets, payers have a significant and growing influence on a product’s commercial success. The need to demonstrate clinical and economic evidence of a product to providers, healthcare decision-makers and payers is becoming the central component to a product’s success.
MarksMan Healthcare Communications is a Health Economic and Outcomes Research (HEOR), Medical Writing and Healthcare Analytics consulting, committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories. We utilise the expertise of our trained professionals to provide accurate, consistent and concise product, disease and therapeutic area information.
Our experienced and trained analytics team provides HEOR, Real Wold Evidence (RWE) and market access support to large and small life science companies. We further provide services pertaining to “Medical Affairs, Medical Devices, Real World Data Curation and Healthcare Analytics”
Concerns about the consistency of the post-marketing surveillance (PMS) for safety of medical devices is well known across the world. Only around 13% of post-marketing surveillance (PMS) clinical studies are completed on medical devices.[1] This is because new products or line extensions are launched frequently, even before full clinical trials of the parent device are […]
With all stakeholders increasingly realising the value real-world evidence (RWE) studies can bring into the healthcare delivery, newer applications of RWE are being discovered with each passing day. RWE has the potential to tremendously enhance the speed of patient access to new drugs. With this background, it is absolutely essential that the quality of RWE […]
Real-World Data (RWD), from which Real-World Evidence (RWE) is generated, has the unique capability of depicting real-world outcomes. RWD can also reduce timelines for research and development, and generate profound insights into the disease process. However, RWD from a single source often suffers from bias relating to equipment, lack of phenotypic diversity, limited training models, […]
